Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (41-50 of 127) with videos related to

Pageof 13
Sort By:
Thoracic Cancer|September 20, 2024
Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancerShuta Ohara, Kenichi Suda, Akira Hamada, et al.
Clinical Lung Cancer|November 9, 2021
Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung CancerKenichi Suda, Shuta Ohara, Toshio Fujino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Tatsuya Katayama, et al.
Anticancer Research|December 7, 2016
Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung CancerTsukihisa Yoshida, Tatsuro Okamoto, Tokujiro Yano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2017
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer TransformationKenichi Suda, Isao Murakami, Hui Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2013
Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free intervalKenji Tomizawa, Simon Ito, Kenichi Suda, et al.
Plos One|April 22, 2016
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL ExpressionKatsuaki Sato, Kenichi Suda, Shigeki Shimizu, et al.
Biomolecules|September 11, 2019
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung AdenocarcinomasKenichi Suda, Masaki Shimoji, Shigeki Shimizu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinibKenichi Suda, Kenji Tomizawa, Makiko Fujii, et al.
Chinese Medical Journal Pulmonary and Critical Care Medicine|August 22, 2024
Pyroptosis: A promising target for lung cancer therapyWensheng Zhou, Lishu Zhao, Hao Wang, et al.
Pageof 13

Showing results (41-50 of 127) with videos related to

Sort By:
Pageof 13
Thoracic Cancer|September 20, 2024
Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancerShuta Ohara, Kenichi Suda, Akira Hamada, et al.
Clinical Lung Cancer|November 9, 2021
Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung CancerKenichi Suda, Shuta Ohara, Toshio Fujino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Tatsuya Katayama, et al.
Anticancer Research|December 7, 2016
Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung CancerTsukihisa Yoshida, Tatsuro Okamoto, Tokujiro Yano, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2017
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer TransformationKenichi Suda, Isao Murakami, Hui Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2013
Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free intervalKenji Tomizawa, Simon Ito, Kenichi Suda, et al.
Plos One|April 22, 2016
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL ExpressionKatsuaki Sato, Kenichi Suda, Shigeki Shimizu, et al.
Biomolecules|September 11, 2019
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung AdenocarcinomasKenichi Suda, Masaki Shimoji, Shigeki Shimizu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinibKenichi Suda, Kenji Tomizawa, Makiko Fujii, et al.
Chinese Medical Journal Pulmonary and Critical Care Medicine|August 22, 2024
Pyroptosis: A promising target for lung cancer therapyWensheng Zhou, Lishu Zhao, Hao Wang, et al.
Pageof 13